{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~9 mi. (Birmingham, Alabama, +144 more cities)
facility
The University of Alabama at Birmingham ( Site 0010)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
city
~9 mi. (Birmingham, Alabama, +133 more cities)
facility
University of Alabama at Birmingham
drug
bortezomib, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~9 mi. (Birmingham, Alabama, +176 more cities)
facility
University of Alabama - Birmingham ( Site 3061)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~9 mi. (Birmingham, Alabama, +454 more cities)
facility
University of Alabama at Birmingham Cancer Center, +1 more facility
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~9 mi. (Birmingham, Alabama, +825 more cities)
facility
University of Alabama at Birmingham Cancer Center
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
city
~9 mi. (Birmingham, Alabama, +240 more cities)
facility
University of Alabama at Birmingham Cancer Center
condition
Endometrial Adenocarcinoma, +5 more conditions
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
city
~9 mi. (Birmingham, Alabama, +199 more cities)
facility
Research Site
drug
bevacizumab, +2 more drugs
drug type
immunotherapy, +1 more type
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
city
~9 mi. (Birmingham, Alabama, +160 more cities)
facility
University of Alabama at Birmingham Cancer Center
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +1 more type